Markey McNutt, MD
Clinical Genetics (M.D.) · Dallas, TXNPI 1679893010
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $187,979 of the $246,965 with a category attached, or 76.1%. Ultragenyx Pharmaceutical Inc. accounts for 60.2% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $146,763, more than ten times the $7,867 reported in 2019. Among clinical genetics (m.d.) clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $1543.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ultragenyx Pharmaceutical Inc.$149K
- Biomarin Pharmaceutical Inc.$40K
- Amgen$33K
- Amicus Therapeutics, Inc.$8K
- Chiesi USA, Inc.$5K
- PTC Therapeutics, Inc.$4K
- plus $10K from 12 others
Across 62 payments — averaging $3600.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$66K
- Amgen$64K
- PTC Therapeutics, Inc.$51K
- Travere Therapeutics, Inc.$21K
- Modernatx, Inc.$21K
What the payments were for
- Consulting fees$187,97976%
- Speaking & faculty fees$43,76318%
- Travel & lodging$7,3213%
- Food & beverage$4,1962%
- Education$3,7062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 15 | $148,672 |
| Biomarin Pharmaceutical Inc. | 43 | $39,624 |
| Amgen(2 entities) | 53 | $32,597 |
| Amicus Therapeutics, Inc. | 2 | $7,527 |
| Chiesi USA, Inc. | 4 | $4,925 |
| PTC Therapeutics, Inc. | 7 | $3,661 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $3,559 |
| Mirum Pharmaceuticals, Inc. | 1 | $1,625 |
| Eton Pharmaceuticals, Inc. | 3 | $1,327 |
| Applied Therapeutics, Inc. | 1 | $1,125 |
| AstraZeneca | 1 | $820 |
| Modernatx, Inc. | 8 | $636 |
| Cycle Pharmaceuticals Inc | 1 | $600 |
| Sanofi | 5 | $176 |
| Intrabio Inc | 1 | $37 |
| Orchard Therapeutics North America | 1 | $26 |
| Dexcom, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RAVICTI$31,340
- Palynziq$14,746
- POMBILITI$7,527
- OPFOLDA$7,527
- Kuvan$4,427
- DOJOLVI$3,200
- LAMZEDE$2,975
- CTEXLI$1,625
- Strensiq$820
- Nityr$600
- GALZIN$112
- CARGLUMIC ACID$112
- BETAINE ANHYDROUS$112
- NITISINONE$112
How this compares
$246,965 in reported general payments places this provider in the 90th percentile of 37 clinical genetics (m.d.) providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RavictiGlycerol Phenylbutyrate | 41 | $3,320,965 |
| PalynziqPegvaliase-Pqpz | 31 | $791,528 |
| CerdelgaEliglustat Tartrate | 12 | $386,228 |
| Sodium Phenylbutyrate | 15 | $66,843 |
| Sodium Chloride0.9 % Sodium Chloride | 17 | $487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenRavicti | $32,597 | $3,320,96541 claims |
| Biomarin Pharmaceutical Inc.Palynziq | $39,624 | $791,52831 claims |
| SanofiCerdelga | $176 | $386,22812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 37 clinical genetics (m.d.) providers in Texas.
Other clinical genetics (m.d.) in Dallas
- Joseph GoldsteinDallas$5.5M
- Steven BloomDallas$55
- Joseph RayGalveston$642K
- Hope NorthrupHouston$180K
- Paul HillmanHouston$68K
- Erin CooneyLeague City$44K
- Brendan LeeHouston$28K
- David RodriguezHouston$28K
- Fernando ScagliaHouston$16K
- Candace GambleFort Worth$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.